Abstract 2170
Background
The single-arm MONO trial (NCT01197885) assessed IMAB362 (600 mg/m2) monotherapy as salvage therapy in GA/GEJA patients and showed a 30% disease control rate. The FAST trial (NCT01630083) assessed IMAB362 (loading dose 800 mg/m2 then 600 mg/m2) combination therapy as 1st line therapy (IMAB362+EOX followed by single agent IMAB362 maintenance until disease progression [DP]) vs EOX alone in GA/GEJA patients. IMAB362+EOX significantly prolonged progression-free and overall survival. We describe the MONO and FAST PRO results.
Methods
EORTC QLQ-C30 and STO22 were collected at baseline, end of IMAB362 treatment (EOT), and every 8 wks post-EOT in MONO; and at baseline, Cycle 5, EOX EOT, and post-EOT every 12 wks until DP in FAST. Both studies used mixed model repeated measures (MMRM) assuming missing at random to assess HRQoL changes from baseline. The proportion of MONO patients per minimally clinically important difference (MCID) category (deterioration, no change, improvement) was evaluated at EOT; in FAST, time to HRQoL deterioration (TTD) based on MCID thresholds was assessed using Kaplan-Meier estimates and Cox models.
Results
Patients in MONO (n = 40) had stable scores in all STO22 domains but deteriorated in C30 functional (role, cognitive and physical) and symptom scales (fatigue, insomnia, pain, nausea/vomiting and appetite loss). MONO treatment responders (n = 9) showed less deterioration in C30 scales. Most patients stayed stable or had clinically meaningful improvement in HRQoL. In FAST (EOX n = 74, IMAB362+EOX n = 68), a significant difference in change from baseline was only seen for the nausea/vomiting symptom scale (P=.01) favoring EOX. IMAB362+EOX delayed TTD for global health status, trouble belching, eating restrictions, feeling tense, pain interference, acid indigestion/burning, shortness of breath and HRQoL vs EOX (all P<.05). Patients remaining on IMAB362 alone post EOX EOT generally showed better HRQoL and physical functioning than EOX alone.
Conclusions
For patients with advanced CLDN18.2 expressing GA/GEJA, IMAB362 maintained HRQoL and delayed TTD in both monotherapy and combination chemotherapy settings.
Clinical trial identification
NCT01197885 and NCT01630083.
Legal entity responsible for the study
Astellas Pharma, Inc.
Funding
Astellas Pharma, Inc.
Editorial Acknowledgement
Disclosure
R. Morlock: Employee: Astellas; Personal fees: Abbot Medical Optics, Ironwood, Genetech. M.R. Krukas-Hampel: Employee: IQVIA, contracted to do this analysis by Astellas. Ö. Türeci: Stock option owner, ex-shareholder, co-founder, CEO: Ganymed AG; Consultancy fee: Astellas; Several patent families are pending, issued, or licensed. Those relevant to this work have been acquired by Astellas.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract